| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Matairesinoside targets TMEM16A (ANO1), a calcium-activated chloride channel. TMEM16A is overexpressed in various cancers and is involved in cell proliferation, migration, and invasion. By targeting TMEM16A, Matairesinoside reduces lung cancer cell growth, migration, and invasion while inducing apoptosis. It also has antibacterial, antioxidant, and virus-cell fusion inhibitory activities.
|
|---|---|
| ln Vitro |
At 46.7%, matairesinoside exhibits a high level of virus-cell fusion inhibitory activity[1]. With an IC50 of 2.19 μg/mL, matairesinoside exhibits significant free radical scavenging activity in the DPPH assay[2]. Pseudomonas aeruginosa is the organism that matairesinoside is particularly active against (MIC of 0.001 mg/mL)[2].
In vitro, Matairesinoside significantly reduces lung cancer cell growth, migration, and invasion while inducing apoptosis. Gene knockdown and overexpression experiments demonstrate that TMEM16A is the direct target of Matairesinoside. Western blot analysis elucidates the associated signaling pathways involved in tumor suppression. The compound also exhibits antibacterial and antioxidant activities. |
| ln Vivo |
In vivo data for Matairesinoside is not extensively reported in publicly available sources. As a lignan with anticancer activity against lung cancer cells in vitro, the compound has potential applications in animal models of lung cancer. However, specific published in vivo efficacy studies are not detailed in the current literature. Matairesinoside is primarily used as a research tool for studying cancer biology and natural product pharmacology.
|
| Enzyme Assay |
The in vitro TMEM16A inhibition assay for Matairesinoside is conducted using cells expressing TMEM16A. The compound's effects on TMEM16A activity are measured using patch-clamp electrophysiology or fluorescence-based membrane potential assays. Cell growth, migration, and invasion are assessed using standard assays such as MTT, wound healing, and transwell assays. Apoptosis is assessed by flow cytometry using Annexin V/PI staining.
|
| Cell Assay |
Cellular assays for Matairesinoside are conducted in lung cancer cell lines. Cells are treated with varying concentrations of Matairesinoside. Cell viability and proliferation are measured using standard assays such as MTT or CellTiter-Glo. Cell migration and invasion are evaluated using transwell or wound healing assays. Apoptosis is assessed by flow cytometry using Annexin V/PI staining. The involvement of TMEM16A is confirmed by gene knockdown and overexpression experiments.
|
| Animal Protocol |
In vivo studies for Matairesinoside would typically involve xenograft mouse models of lung cancer. The compound would be administered via oral or intraperitoneal routes. Efficacy would be assessed by measuring tumor growth inhibition. However, specific published in vivo protocols for Matairesinoside are not available in the current literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Matairesinoside is not extensively reported in publicly available sources. The compound has a molecular weight of 522.54 and a molecular formula of C26H34O11. It has a CAS number of 23202-85-9. As a glycoside, it is expected to have moderate bioavailability. Detailed PK parameters such as half-life and bioavailability are not available.
|
| Toxicity/Toxicokinetics |
Toxicity data for Matairesinoside is limited. As with all research compounds, Matairesinoside is intended for research use only and not for human therapeutic applications. Standard in vitro cytotoxicity assays and in vivo tolerability studies would be required for a complete toxicity assessment.
|
| References | |
| Additional Infomation |
Matairesinoside is a lignan, a structure in which a phenolic hydroxyl group of (-)-materacilol is replaced by a β-D-glucose group. It is a plant metabolite. It is a γ-lactone, lignan, β-D-glucoside, monosaccharide derivative, and a member of the guaiacol family. Its function is related to that of (-)-materacilol. Matairesinoside has been reported to be found in Symplocos setchuensis, Saussurea parviflora, and other organisms with relevant data.
Matairesinoside (mogroside; CAS 23202-85-9) is a lignan with antibacterial and antioxidant activities. It displays virus-cell fusion inhibitory activity. It significantly reduces lung cancer cell growth, migration, and invasion while inducing apoptosis, with TMEM16A as the direct target. Matairesinoside is used in cancer research. It is for research use only. |
| Molecular Formula |
C26H32O11
|
|---|---|
| Molecular Weight |
520.53
|
| Exact Mass |
520.194
|
| CAS # |
23202-85-9
|
| PubChem CID |
486612
|
| Appearance |
White to off-white solid powder
|
| Vapour Pressure |
9.72E-26mmHg at 25°C
|
| LogP |
0.162
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
37
|
| Complexity |
737
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
COC1=C(C=CC(=C1)C[C@H]2COC(=O)[C@@H]2CC3=CC(=C(C=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OC)O
|
| InChi Key |
AAGCATAPYOEULE-LHHMAMHXSA-N
|
| InChi Code |
InChI=1S/C26H32O11/c1-33-19-9-13(3-5-17(19)28)7-15-12-35-25(32)16(15)8-14-4-6-18(20(10-14)34-2)36-26-24(31)23(30)22(29)21(11-27)37-26/h3-6,9-10,15-16,21-24,26-31H,7-8,11-12H2,1-2H3/t15-,16+,21+,22+,23-,24+,26+/m0/s1
|
| Chemical Name |
(3R,4R)-4-[(4-hydroxy-3-methoxyphenyl)methyl]-3-[[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl]oxolan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (192.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.80 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9211 mL | 9.6056 mL | 19.2112 mL | |
| 5 mM | 0.3842 mL | 1.9211 mL | 3.8422 mL | |
| 10 mM | 0.1921 mL | 0.9606 mL | 1.9211 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
